Leny Nascimento da Motta Passos1, Márcia Poinho Encarnação de Moraes1, Bruna Tamegão-Lopes2, José Alexandre Rodrigues de Lemos3, Paulo Roberto de Lima Machado4, Marcelo Távora Mira5, Sinésio Talhari6. 1. Departamento de Ensino e Pesquisa, Hematologia, Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas, Manaus, AM, Brazil. 2. Departamento de Imunologia Básica e Epidemiologia Básica, Faculdade Metropolitana da Amazônia, Manaus, AM, Brazil. 3. Departamento de Laboratórios de Biologia Celular e Molecular do Hemocentro do PRA, Instituto de Ciências Biológicas, Universidade Federal do Pará, Belém, PA, Brazil. 4. Serviço de Imunologia, Universidade Federal da Bahia, Salvador, BA, Brasil. 5. Programa de Pós-Graduação em Ciências da Saúde, Centro de Ciências Biológicas e da Saúde de Curitiba, Pontifícia Universidade Católica do Paraná, Curitiba, PR, Brasil. 6. Departamento de Dermatologia Tropical, Fundação de Medicina Tropical Heitor Dourado do Amazonas. Clínica de Dermatologia Talhari, Universidade Nilton Lins do Amazonas, Manaus, AM, Brazil.
Abstract
INTRODUCTION: The prevalence of human T-cell lymphotropic virus types 1 and 2 (HTLV-1/2) infection is heterogeneous across different populations. We tested the hypothesis that HTLV-1/2 infection occurs more often in dermatological patients. METHODS: A total of 1,091 patients from a tropical dermatology clinic were tested for HTLV-1/2. In parallel, 6865 first-time blood donors from the same geographic area were screened for HTLV-1/2; HTLV-1/2 positive blood donors underwent dermatological examinations. RESULTS: The prevalence of HTLV-1/2 in first-time blood donors was 0.14%. No co-occurrence of HTLV-1/2 infection and dermatological conditions was observed. CONCLUSIONS: Our results challenge the hypothesis that HTLV-1/2 infection occurs more often in dermatological patients.
INTRODUCTION: The prevalence of human T-cell lymphotropic virus types 1 and 2 (HTLV-1/2) infection is heterogeneous across different populations. We tested the hypothesis that HTLV-1/2 infection occurs more often in dermatological patients. METHODS: A total of 1,091 patients from a tropical dermatology clinic were tested for HTLV-1/2. In parallel, 6865 first-time blood donors from the same geographic area were screened for HTLV-1/2; HTLV-1/2 positive blood donors underwent dermatological examinations. RESULTS: The prevalence of HTLV-1/2 in first-time blood donors was 0.14%. No co-occurrence of HTLV-1/2 infection and dermatological conditions was observed. CONCLUSIONS: Our results challenge the hypothesis that HTLV-1/2 infection occurs more often in dermatological patients.